Nyxoah SA income statement

In fiscal 2025, Nyxoah SA reported revenue of $11.3m, up 131.6% on the year before, operating income of −$94.4m (a -833.2% margin) and net income of −$102m, or −$2.67 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Nyxoah SA: income statement, annual
Fiscal year	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	0	1	3	5	5	11
Cost of revenue	0	0	1	2	2	4
Gross profit	0	1	2	3	3	7
Research and development	3	15	17	29	37	48
Operating income	−13	−31	−34	−49	−64	−94
Interest expense	0	0	0	0	0	0
Income before tax	−14	−29	−32	−48	−61	−101
Income tax	0	4	1	−2	3	1
Net income	−14	−33	−33	−47	−64	−102
Diluted EPS	−$0.77	−$1.37	−$1.27	−$1.67	−$1.96	−$2.67
Diluted shares (average)	18m	24m	26m	28m	33m	38m

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: NSPR vs NYXH HSDT vs NYXH NNOX vs NYXH

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Nyxoah SA's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Nyxoah SA.